100 related articles for article (PubMed ID: 34589997)
1. Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor.
Fujino T; Mitsudomi T
JTO Clin Res Rep; 2021 Mar; 2(3):100134. PubMed ID: 34589997
[No Abstract] [Full Text] [Related]
2. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
Mizuuchi H; Suda K; Murakami I; Sakai K; Sato K; Kobayashi Y; Shimoji M; Chiba M; Sesumi Y; Tomizawa K; Takemoto T; Sekido Y; Nishio K; Mitsudomi T
Cancer Sci; 2016 Apr; 107(4):461-8. PubMed ID: 26845230
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
4. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
5. MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells.
Kitowska K; Gorska-Arcisz M; Antoun D; Zarczynska I; Czaplinska D; Szczepaniak A; Skladanowski AC; Wieczorek M; Stanczak A; Skupinska M; Sadej R
Front Oncol; 2021; 11():633410. PubMed ID: 33898310
[TBL] [Abstract][Full Text] [Related]
6. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
[TBL] [Abstract][Full Text] [Related]
7. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Jacobsen K; Bertran-Alamillo J; Molina MA; Teixidó C; Karachaliou N; Pedersen MH; Castellví J; Garzón M; Codony-Servat C; Codony-Servat J; Giménez-Capitán A; Drozdowskyj A; Viteri S; Larsen MR; Lassen U; Felip E; Bivona TG; Ditzel HJ; Rosell R
Nat Commun; 2017 Sep; 8(1):410. PubMed ID: 28871105
[TBL] [Abstract][Full Text] [Related]
8. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
[TBL] [Abstract][Full Text] [Related]
10. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
11. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
12. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
13. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z
Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370
[TBL] [Abstract][Full Text] [Related]
14. A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition.
Miyoshi S; Kato T; Katayama H; Ito R; Mizuno Y; Okura T; Higaki J
Onco Targets Ther; 2015; 8():783-7. PubMed ID: 25914548
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
[TBL] [Abstract][Full Text] [Related]
16. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Gou LY; Li AN; Yang JJ; Zhang XC; Su J; Yan HH; Xie Z; Lou NN; Liu SY; Dong ZY; Gao HF; Zhou Q; Zhong WZ; Xu CR; Wu YL
Oncotarget; 2016 Aug; 7(32):51311-51319. PubMed ID: 27259997
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G; Bahcall M; Spurr LF; Che J; Ricciuti B; Leonardi GC; Lo YC; Li YY; Lamberti G; Nguyen T; Milan MSD; Venkatraman D; Umeton R; Paweletz CP; Albayrak A; Cherniack AD; Price KS; Fairclough SR; Nishino M; Sholl LM; Oxnard GR; Jänne PA; Awad MM
Clin Cancer Res; 2020 Jun; 26(11):2615-2625. PubMed ID: 32034073
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer.
Bonanno L; Jirillo A; Favaretto A
Curr Drug Targets; 2011 Jun; 12(6):922-33. PubMed ID: 21443472
[TBL] [Abstract][Full Text] [Related]
19. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]